Название продукции:4-(4-Ethylpiperazino)aniline
IUPAC Name:4-(4-ethylpiperazin-1-yl)aniline
- CAS：115619-01-7
- Молекулярная формула：C12H19N3
- Чистота：95%+
- Номер в каталоге：CM169872
- Молекулярная масса：205.31
Только для использования в НИОКР..
Информация о продукции
- Номер CAS:115619-01-7
- Молекулярная формула:C12H19N3
- Точка плавления:-
- Smiles-код:C(C)N1CCN(CC1)C2=CC=C(C=C2)N
- Плотность:
- Номер в каталоге:CM169872
- Молекулярная масса:205.31
- Точка кипения:364.4°C at 760 mmHg
- Номер Mdl:MFCD00702246
- Хранение:Keep in dark place, store at 2-8°C.
Category Infos
- Piperazines
- Piperazine is an organic compound consisting of a six-membered ring containing two nitrogen atoms in opposite positions in the ring. The chemical formula of piperazine is C4H10N2, and it is an important pharmaceutical intermediate. Pyrimidines and piperazines are known to be the backbone of many bulk compounds and important core structures for approved drugs; studies have shown that combining a pyridine ring with a piperazine moiety within a single structural framework enhances biological activity.
- Benzenes
- Benzene is an important organic compound with the chemical formula C6H6, and its molecule consists of a ring of 6 carbon atoms, each with 1 hydrogen atom. Benzene is a sweet, flammable, colorless and transparent liquid with carcinogenic toxicity at room temperature, and has a strong aromatic odor. It is insoluble in water, easily soluble in organic solvents, and can also be used as an organic solvent itself. The ring system of benzene is called benzene ring, and the structure after removing one hydrogen atom from the benzene ring is called phenyl. Benzene is one of the most important basic organic chemical raw materials. Many important chemical intermediates can be derived from benzene through substitution reaction, addition reaction and benzene ring cleavage reaction.
Column Infos
- Infigratinib
- Sept. 06, 2023, positive feedback from the U.S. FDA and the EU EMA on key elements of the trial design for PROPEL3, its pivotal Phase 3 study of infigratinib in children with achondroplasia.
Achondroplasia is the most common cause of disproportionate short stature, affecting approximately 55,000 people in the United States and European Union, including up to 10,000 children and adolescents with open growth plates. Achondroplasia impacts overall health and quality of life, leading to medical complications such as obstructive sleep apnea, middle ear dysfunction, kyphosis, and spinal stenosis. The condition is uniformly caused by an activating mutation in FGFR3.
Infigratinib is an oral small molecule designed to inhibit FGFR3 and target achondroplasia at its source. It is incredibly exciting that infigratinib has the potential to become the first effective oral treatment option to improve growth, enhance functionality and decrease complications.
Поиск 
+86 21 5895 0110 
